 |
|
|
|
 |
|
|
| Article 1 to 10 out of 24 concerning Acambis plc
|
-
Acambis extends Sanofi Pasteur licensing agreement on single-dose JE vaccine to India and Indian subcontinent
(26 Mar 2008)
Acambis plc announced that it has extended its ChimeriVax(tm)-JE vaccine licensing agreement with sanofi pasteur, the vaccines division of the sanofi-aventis Group, to include India and the Indian subcontinent.Acambis announced in February 2007 that ...
-
Acambis initiates pre-clinical testing with herpes vaccine from Harvard Medical School
(27 Feb 2008)
Acambis plc announced that it has initiated pre-clinical trials with a herpes vaccine, licensed from Harvard University through its Office of Technology Development, with a view to submitting an Investigational New Drug (IND) application in 2009.The ...
-
Acambis concludes C. difficile vaccine formulation work on schedule and will commence proof-of-concept trial in 2008
(20 Dec 2007)
Acambis plc announced an update on its programme to develop the world's first vaccine against Clostridium difficile-associated disease (CDAD). C. difficile infection is the most common cause of hospital-acquired diarrhoea in the developed world, ...
-
Acambis announces global collaboration agreement with Sanofi Pasteur on leading West Nile vaccine
(15 Nov 2007)
Acambis plc announced that it has signed an exclusive global collaboration agreement with Sanofi Pasteur, the vaccines division of sanofi-aventis Group, for Acambis' ChimeriVax(TM)-West Nile vaccine. Under the terms of the agreement, Acambis will ...
-
FDA licenses Acambis' ACAM2000 vaccine for protection against smallpox
(04 Sep 2007)
Acambis plc announced that the US Food and Drug Administration (FDA) has approved its ACAM2000 (Smallpox (Vaccinia) Vaccine, Live) vaccine for active immunisation against smallpox disease for persons determined to be at high risk for smallpox ...
-
Acambis' universal influenza vaccine enters Phase 1 trial
(19 Jul 2007)
Acambis plc announces that it has initiated a Phase 1 clinical trial of its universal influenza vaccine candidate, ACAM-FLU-A.The vaccine candidate is designed for targeting all 'A' strains of the influenza virus. As such, it has the potential to be ...
-
Acambis sells Berna Products to Crucell for $16.5m
(05 Oct 2006)
Acambis plc announces the sale of its Berna Products Corporation business to Crucell NV . Berna Products is no longer a strategic asset for Acambis following the termination of the ARILVAX licensing agreement, which was announced on 12 September. ...
-
Acambis announces encouraging data from Phase 2 trial of West Nile virus vaccine
(13 Sep 2006)
Acambis plc announced preliminary results from the first component of a Phase 2 clinical trial of its investigational vaccine against West Nile virus, ChimeriVax-West Nile.In the first part of this Phase 2 trial, Acambis evaluated the safety, ...
-
Peter Fellner to become new Chairman of Acambis
(13 Jul 2006)
Acambis announces that, effective from 1 October 2006, Alan Smith will retire as Chairman, and from the Board, of Acambis and will be succeeded by Dr Peter Fellner.Alan Smith, 61, has been Chairman of Acambis since May 1999, having joined the Board ...
-
Acambis completes enrollment of Phase 3 JE vaccine trials ahead of schedule
(20 Apr 2006)
Acambis plc announced that it has completed enrolment into two pivotal Phase 3 trials of its investigational vaccine against Japanese encephalitis (JE), ChimeriVax-JE, ahead of schedule. With this milestone met, Acambis remains on track for ...
Additional information
Acambis plc
Cambridge, United Kingdom
Company
|
|
|
|
|
|
Top
